English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Objective: To review the incidence of secondary adrenal insufficiency (SAI) in nasopharyngeal carcinoma (NPC) patients treated with intensity-modulated radiotherapy (IMRT), and to determine the characteristics and risk factors associated with the development of SAI. Methods: A total of 143 NPC patients diagnosed between 2009 and 2010 and treated with radical IMRT were retrospectively reviewed. The low-dose short Synacthen test was used to determine the presence of SAI. Using Kaplan-Meier method and Cox proportional hazard regression, the relationship between development of SAI and various clinical parameters was evaluated. Results: The median follow-up period was 65 months. The median mean and median maximum doses to the pituitary gland were 56.3 Gy (range, 19.1-72.0 Gy) and 59.5 Gy (range, 28.5-73.8 Gy), respectively. The cumulative incidences of SAI at 2 and 5 years post-treatment were 7.7% and 17.5%, respectively. The median time to onset of SAI was 30.5 (range, 16-82) months after radiotherapy. Multiple Cox regression analysis revealed that receiving additional radiotherapy after a definitive course of radiotherapy was an independent risk factor for the development of SAI, with a relative risk of 6.598 (95% confidence interval = 1.554-28.013; p = 0.01). Conclusion: SAI is common in NPC patients treated with IMRT. Regular monitoring of hypothalamic-pituitary– adrenal axis hormone function should start as early as 6 months to 1 year post-treatment so that treatment can be initiated early if indicated, especially in patients who have received additional radiotherapy after definitive radiotherapy for NPC.

Secondary Adrenal Insufficiency: A Cross-sectional Study of Nasopharyngeal Carcinoma Patients after Treatment with Intensity-modulated Radiotherapy